Markets are rebounding today after a horrible beginning to the week. Looking in the biotech sector, I’m seeing a sea of green with very few blemishes. I’ve also been able to dig out a few great opportunities in the sector. Here they are…
Gilead Sciences Is Likely To See Long Run Gains
Gilead Sciences, Inc. (NASDAQ: GILD)
I’ve talked about Gilead Sciences quite a bit lately; and for good reason. When we talk about this company, we’re talking about a company whose stock is highly discounted; and with their control of the HIV and HCV markets, the discount really doesn’t make sense. That in and of itself should get this stock moving over time. It’s also important to note that GILD recently received approval in Japan for their HCV treatment, Harvoni. This will likely prove to be just what investors want to see as concerns over the company’s HCV franchise are what’s causing investors not to push this stock up. Nonetheless, I don’t think that the HCV franchise is in danger; and like several main stream analysts, I’m expecting to see great things out of this great company. With that said, it may be well worth your while to start looking for pullbacks as they will likely prove to be great entrance opportunities.
BG Medicine Stock Has Plenty Of Upside Potential
BG Medicine, Inc. (NASDAQ: BGMD)
BG Medicine is another in the biotech sector that I have incredibly high hopes for. Earlier this week, the company announced that the Architect Galectin-3 assay is now available. This is an automated blood test that has been cleared by the FDA for use in conjunction with clinical evaluation as an aide in assessing the prognosis of patients with chronic heart failure. Also, earlier today, the company announced a one-for-four reverse stock split. The split took effect upon the close of the market yesterday and was designed to meet the $1.00 per share minimum requirement for continued listing on the NASDAQ Capital Market. As mentioned above, I’m expecting to see more growth moving forward. So, keep an eye out for dips and buying opportunities.
Oculus Innovative Sciences Continues Gains On Patent Newsletter
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS)
Finally, Oculus Innovative Sciences announced yesterday that they have received a new U.S. Patent for Microcyn Technology hypochlorous acid in the treatment of atopic dermatitis. As a result of the news, the stock was up in a big way yesterday and continues to climb today. Currently (12:02), OCLS is trading at $1.63 per share after a gain of 3.82% so far today. With the new patent, OCLS will have exclusivity for the use of hypochlorous acid with a broad range of activity in the treatment of atopic dermatitis until 2027. With that said, I’m expecting to see much more by way of gains in the stock moving forward.
Do You Know Of Any Others?
Do you know of any other strong opportunities in the biotech sector? If so, let us know in the comments below!